Your browser doesn't support javascript.
loading
Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Edahiro, Taro; Kawase, Takakazu; Nagoshi, Hisao; Fujino, Keita; Toishigawa, Kayo; Miyama, Takahiko; Mino, Tatsuji; Yoshida, Tetsumi; Morioka, Takehiko; Hirata, Yuji; Noma, Mitsunori; Fujii, Teruhisa; Nishizawa, Masatoshi; Fukushima, Noriyasu; Ichinohe, Tatsuo.
Afiliação
  • Edahiro T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Kawase T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Nagoshi H; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Fujino K; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Toishigawa K; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Miyama T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Mino T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Yoshida T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Morioka T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Hirata Y; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Noma M; Division of Transfusion Medicine, Hiroshima University Hospital, Hiroshima, Japan.
  • Fujii T; Division of Transfusion Medicine, Hiroshima University Hospital, Hiroshima, Japan.
  • Nishizawa M; Next Generation Development of Genome and Cellular Therapy Program, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Fukushima N; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
  • Ichinohe T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Hematology ; 26(1): 186-198, 2021 Dec.
Article em En | MEDLINE | ID: mdl-33594942
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Transplante de Células-Tronco Hematopoéticas / Neoplasias Hematológicas / Condicionamento Pré-Transplante Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Hematology Assunto da revista: HEMATOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Transplante de Células-Tronco Hematopoéticas / Neoplasias Hematológicas / Condicionamento Pré-Transplante Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Hematology Assunto da revista: HEMATOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão